Non-embryonic Stem Cells Modulate Macrophage Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods are inadequate in effectively modulating macrophage activation to reduce inflammation in conditions such as CNS injuries, as they fail to specifically target neurotoxic or promote neuroprotective activation states, leading to inadequate treatment outcomes for conditions like stroke, multiple sclerosis, and other inflammatory diseases.
Innovation Solution
Administration of non-embryonic stem cells that naturally express and secrete modulatory factors, such as CCL21 and TGFβ, to modulate macrophage activation, shifting the immune response from neurotoxic to neuroprotective, thereby reducing inflammation and promoting tissue repair.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current anti-inflammatory methods are used, then general inflammation may be reduced, but they fail to specifically modulate macrophage activation states, resulting in inadequate treatment of neurotoxic activation
Solution Approach 1:
The patent applies local quality by using non-embryonic stem cells that secrete specific modulatory factors (TGFβ, CCL21, IL-10) to target specific macrophage activation states. Instead of general anti-inflammatory treatment, the therapy delivers specific biochemical signals that selectively modulate M1 vs M2 macrophage polarization, achieving localized immunomodulation at the molecular level within the inflammatory microenvironment
Solution Approach 2:
The patent employs non-embryonic stem cells as intermediary carriers that secrete modulatory factors (TGFβ, CCL21, IL-10) to indirectly regulate macrophage activation. These stem cells act as mediators between the therapeutic intervention and the macrophages, delivering specific biochemical signals that shift macrophage polarization without direct contact or genetic modification of the macrophages themselves
2Reliability
If non-embryonic stem cells are administered to modulate macrophage activation, then neuroprotective activation is increased and neurotoxic activation is reduced, but the complexity of cell selection and potency assessment increases
Solution Approach 1:
The patent applies preliminary action by establishing comprehensive cell banking and potency assessment protocols before clinical administration. Non-embryonic stem cells are pre-screened for their ability to secrete modulatory factors (TGFβ, CCL21, IL-10) and pre-characterized for immunomodulatory potency. This advance preparation ensures consistent quality and efficacy while streamlining the clinical implementation process
Solution Approach 2:
The patent utilizes parameter changes by defining specific measurable characteristics for cell selection and potency assessment, including secretion levels of modulatory factors (TGFβ, CCL21, IL-10), cell surface markers, and in vitro macrophage modulation capacity. These quantifiable parameters enable systematic quality control and standardization of the cellular therapy product
3Reliability
If macrophages are shifted from TH1 to TH2 response, then neuroprotective effects are enhanced, but the time required to achieve desired activation state modulation increases
Solution Approach 1:
The patent applies continuity of useful action by administering non-embryonic stem cells that continuously secrete modulatory factors (TGFβ, CCL21, IL-10) over an extended period. The stem cells establish persistent presence in the inflammatory microenvironment, providing ongoing immunomodulatory signals that progressively shift macrophage polarization from M1 to M2 state, maintaining therapeutic pressure without requiring repeated interventions
Solution Approach 2:
The patent employs preliminary action by pre-conditioning non-embryonic stem cells in vitro to enhance their secretory capacity for modulatory factors before administration. Cells are cultured under specific conditions that upregulate TGFβ, CCL21, and IL-10 production, ensuring they are primed to immediately exert neuroprotective effects upon implantation, thereby reducing the lag time for therapeutic action
Data Source
Figure 1
Figure 2A~2D
Figure 3A~3B
AI summary
The invention provides methods for treating pathological conditions associated with an undesirable inflammatory component. The invention is generally directed to reducing inflammation by administering cells that modulate macrophage activation. The invention is also directed to drug discovery methods to screen for agents that modulate the ability of the cells to modulate macrophage activation. The invention is also directed to cell banks that can be used to provide cells for administration to a subject, the banks comprising cells having desired potency to modulate macrophage activation.